Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
IHC is better predictor of Her2 gene amplification by FISH than HercepTest
November 24th, 2005
Immunohistochemistry (IHC) for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by fluorescence in situ hybridization (FISH) than HercepTest in breast carcinoma. According to recent research from Ireland, "Her2 (c-erbB-2/neu) overexpression in breast carcinoma predicts response to the anti-Her2 monoclonal antibody, trastuzumab, and is associated with a poor prognosis. When considering patients for trastuzumab treatment, Her2 protein expression is measured by immunohistochemistry (IHC) and, where staining is equivocal, by fluorescence in situ hybridization (FISH) detection of Her2 gene amplification. This study was done to compare IHC...
Source: Women's Health Weekly (2005-11-24)
|
